Fibrinolytic therapy in suspected acute myocardial infarction. 1994

J Carlsson, and G Rahlf, and U Tebbe

UI MeSH Term Description Entries
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D005260 Female Females
D006342 Heart Rupture, Post-Infarction Laceration or tearing of cardiac tissues appearing after MYOCARDIAL INFARCTION. Post-Infarction Heart Rupture,Cardiac Rupture, Post-Infarction,Cardiac Rupture, Post Infarction,Cardiac Ruptures, Post-Infarction,Heart Rupture, Post Infarction,Heart Ruptures, Post-Infarction,Post Infarction Heart Rupture,Post-Infarction Cardiac Rupture,Post-Infarction Cardiac Ruptures,Post-Infarction Heart Ruptures,Rupture, Post-Infarction Cardiac,Rupture, Post-Infarction Heart,Ruptures, Post-Infarction Cardiac,Ruptures, Post-Infarction Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D013300 Streptokinase Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-. Avelizin,Awelysin,Celiase,Distreptase,Kabikinase,Kabivitrum,Streptase,Streptodecase
D015912 Thrombolytic Therapy Use of infusions of FIBRINOLYTIC AGENTS to destroy or dissolve thrombi in blood vessels or bypass grafts. Fibrinolytic Therapy,Thrombolysis, Therapeutic,Therapeutic Thrombolysis,Therapy, Fibrinolytic,Therapy, Thrombolytic,Fibrinolytic Therapies,Therapeutic Thrombolyses,Therapies, Fibrinolytic,Therapies, Thrombolytic,Thrombolyses, Therapeutic,Thrombolytic Therapies
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

J Carlsson, and G Rahlf, and U Tebbe
April 1994, Lancet (London, England),
J Carlsson, and G Rahlf, and U Tebbe
May 1994, Lancet (London, England),
J Carlsson, and G Rahlf, and U Tebbe
April 1994, Lancet (London, England),
J Carlsson, and G Rahlf, and U Tebbe
March 1997, The New England journal of medicine,
J Carlsson, and G Rahlf, and U Tebbe
February 2004, Current treatment options in cardiovascular medicine,
J Carlsson, and G Rahlf, and U Tebbe
May 1982, Harefuah,
J Carlsson, and G Rahlf, and U Tebbe
February 1987, Revista medica de Chile,
J Carlsson, and G Rahlf, and U Tebbe
February 1972, The New England journal of medicine,
J Carlsson, and G Rahlf, and U Tebbe
December 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology,
J Carlsson, and G Rahlf, and U Tebbe
July 2001, JAMA,
Copied contents to your clipboard!